$13.91
Insights on Alvotech Sa
Revenue is down for the last 2 quarters, 53.39M → 12.43M (in $), with an average decrease of 76.7% per quarter
Netprofit is up for the last 2 quarters, -276.55M → -218.72M (in $), with an average increase of 26.4% per quarter
1.44%
Downside
Day's Volatility :2.0%
Upside
0.57%
51.83%
Downside
52 Weeks Volatility :62.78%
Upside
22.72%
Period | Alvotech Sa | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -12.75% | -0.2% | 0.0% |
6 Months | 47.1% | 9.7% | 0.0% |
1 Year | 64.43% | 10.6% | 0.0% |
3 Years | 24.75% | 18.5% | -22.6% |
Market Capitalization | 3.9B |
Book Value | - $2.68 |
Earnings Per Share (EPS) | -2.08 |
Wall Street Target Price | 19.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -131.24% |
Return On Assets TTM | -19.45% |
Return On Equity TTM | 0.0% |
Revenue TTM | 114.4M |
Revenue Per Share TTM | 0.49 |
Quarterly Revenue Growth YOY | 132.29999999999998% |
Gross Profit TTM | 20.9M |
EBITDA | -287.3M |
Diluted Eps TTM | -2.08 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.53 |
EPS Estimate Next Year | 0.26 |
EPS Estimate Current Quarter | -0.08 |
EPS Estimate Next Quarter | -0.04 |
What analysts predicted
Upside of 36.59%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 31.9M | - |
Net Income | -209.9M | - |
Net Profit Margin | -657.55% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 66.6M | ↑ 108.71% |
Net Income | -170.0M | ↓ 18.98% |
Net Profit Margin | -255.26% | ↑ 402.29% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 36.8M | ↓ 44.8% |
Net Income | -101.5M | ↓ 40.31% |
Net Profit Margin | -276.04% | ↓ 20.78% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 83.0M | ↑ 125.79% |
Net Income | -513.6M | ↑ 405.97% |
Net Profit Margin | -618.55% | ↓ 342.51% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 91.4M | ↑ 10.12% |
Net Income | -551.7M | ↑ 7.43% |
Net Profit Margin | -603.42% | ↑ 15.13% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 23.9M | ↑ 25.22% |
Net Income | -320.5M | ↑ 3625.96% |
Net Profit Margin | -1.3K% | ↓ 1298.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 15.9M | ↓ 33.51% |
Net Income | -276.2M | ↓ 13.83% |
Net Profit Margin | -1.7K% | ↓ 397.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.4M | ↓ 72.32% |
Net Income | 189.3M | ↓ 168.55% |
Net Profit Margin | 4.3K% | ↑ 6052.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 17.8M | ↑ 305.12% |
Net Income | -188.3M | ↓ 199.47% |
Net Profit Margin | -1.1K% | ↓ 5370.31% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 53.4M | ↑ 200.13% |
Net Income | -276.6M | ↑ 46.85% |
Net Profit Margin | -517.99% | ↑ 540.64% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.4M | ↓ 76.72% |
Net Income | -218.7M | ↓ 20.91% |
Net Profit Margin | -1.8K% | ↓ 1241.7% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 474.4M | - |
Total Liabilities | 1.3B | - |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 598.0M | ↑ 26.04% |
Total Liabilities | 733.6M | ↓ 45.32% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 828.4M | ↑ 38.54% |
Total Liabilities | 1.4B | ↑ 89.87% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 950.1M | ↑ 14.68% |
Total Liabilities | 1.9B | ↑ 35.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 828.4M | ↑ 21.27% |
Total Liabilities | 1.4B | ↑ 45.04% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 895.5M | ↑ 8.09% |
Total Liabilities | 1.6B | ↑ 11.37% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 910.7M | ↑ 1.7% |
Total Liabilities | 1.4B | ↓ 10.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 958.8M | ↑ 5.29% |
Total Liabilities | 1.6B | ↑ 16.59% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 950.1M | ↓ 0.91% |
Total Liabilities | 1.9B | ↑ 16.23% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↑ 11.64% |
Total Liabilities | 1.7B | ↓ 8.66% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -88.5M | - |
Investing Cash Flow | -12.9M | - |
Financing Cash Flow | 116.4M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -74.3M | ↓ 16.1% |
Investing Cash Flow | -16.9M | ↑ 31.28% |
Financing Cash Flow | 55.4M | ↓ 52.39% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -228.2M | ↑ 207.11% |
Investing Cash Flow | -40.6M | ↑ 140.39% |
Financing Cash Flow | 254.8M | ↑ 359.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -312.4M | ↑ 36.91% |
Investing Cash Flow | -63.5M | ↑ 56.37% |
Financing Cash Flow | 424.9M | ↑ 66.74% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -64.4M | ↓ 39.76% |
Investing Cash Flow | -10.5M | ↓ 9.47% |
Financing Cash Flow | 128.4M | ↑ 4176.25% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -86.1M | ↑ 33.8% |
Investing Cash Flow | -11.4M | ↑ 8.42% |
Financing Cash Flow | 147.2M | ↑ 14.66% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.9M | ↓ 51.39% |
Investing Cash Flow | -11.4M | ↑ 0.0% |
Financing Cash Flow | -2.7M | ↓ 101.86% |
Sell
Neutral
Buy
Alvotech Sa is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Alvotech Sa | -2.92% | 47.1% | 64.43% | 24.75% | 24.75% |
Neurocrine Biosciences Inc. | -1.26% | 20.07% | 49.07% | 48.24% | 66.16% |
Haleon Plc Spon Ads | 2.79% | 0.0% | 2.67% | 14.3% | 14.3% |
Zoetis Inc. | 3.87% | -4.05% | 0.73% | -1.56% | 58.87% |
Viatris Inc. | -10.49% | 10.09% | 13.4% | -31.25% | -35.25% |
Catalent, Inc. | -3.71% | 39.5% | 43.6% | -47.77% | 17.92% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Alvotech Sa | 55.96 | NA | NA | -0.53 | 0.0 | -0.19 | NA | -2.68 |
Neurocrine Biosciences Inc. | 36.8 | 36.8 | 0.44 | 4.07 | 0.18 | 0.1 | NA | 23.72 |
Haleon Plc Spon Ads | 28.13 | 28.13 | 1.69 | 0.46 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 32.67 | 32.67 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
Viatris Inc. | 224.4 | NA | NA | 2.74 | 0.0 | 0.03 | 0.05 | 16.81 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.25 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Alvotech Sa | Buy | $3.9B | 24.75% | 55.96 | 0.0% |
Neurocrine Biosciences Inc. | Buy | $13.6B | 66.16% | 36.8 | 18.65% |
Haleon Plc Spon Ads | Buy | $38.5B | 14.3% | 28.13 | 9.64% |
Zoetis Inc. | Buy | $77.4B | 58.87% | 32.67 | 27.38% |
Viatris Inc. | Hold | $12.6B | -35.25% | 224.4 | -0.37% |
Catalent, Inc. | Hold | $9.7B | 17.92% | 211.02 | -28.44% |
alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a
Organization | Alvotech Sa |
Employees | 999 |
CEO | Mr. Faysal Kalmoua |
Industry | Services |
Vail Resorts Inc.
$13.91
-0.36%
Boot Barn Holdings Inc
$13.91
-0.36%
Vipshop Holding Ltd.
$13.91
-0.36%
Tanger Inc.
$13.91
-0.36%
Restoration Hardware Holdings, Inc.
$13.91
-0.36%
Willscot Mobile Mini Holding
$13.91
-0.36%
Globalstar Inc.
$13.91
-0.36%
Liberty Global Plc - Class C Shares
$13.91
-0.36%
Life Time Group Holdings, Inc.
$13.91
-0.36%